MilliporeSigma receives the industry's first EXCiPACT certification for cell culture media manufacturing

Ibex Medical Analytics achieves notable milestones with its AI-first approach to cancer diagnostics

Albertsons Companies pharmacies now offer COVID and flu vaccines to help protect communities this respiratory virus season

OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award

Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis

ProJenX announces the formation of its Clinical Advisory Board

Citius Pharmaceuticals' LYMPHIR™ wins FDA approval for relapsed/refractory cutaneous T-cell lymphoma

NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients

Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits

Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.

Updated flu and COVID-19 vaccinations are now available at CVS Pharmacy® and MinuteClinic

$FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma$

FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma

Featured Press Releases

CorrectSequence Therapeutics' CS-101 Achieves Promising Results in First Patient: High-Precision Base Editing Clinical Treatment for Sickle Cell Disease

By CorrectSequence Therapeutics
CorrectSequence Therapeutics
27 Aug 2025

2025 Interim Results and Business Updates Announced by Innovent

By Innovent Biologics
Innovent Biologics
27 Aug 2025

Gvoke VialDx™ (glucagon injection) Launched by American Regent

By American Regent, Inc
American Regent, Inc
27 Aug 2025

Innovent Biologics announces U.S. FDA IND approval for Phase 3 MarsLight-11 study of IBI363 in squamous NSCLC

By Innovent Biologics
Innovent Biologics
25 Aug 2025

Theravance Biopharma completes enrollment in Phase 3 CYPRESS study of Ampreloxetine for neurogenic orthostatic hypotension

By Theravance Biopharma, Inc.
Theravance Biopharma, Inc.
25 Aug 2025

VASTHERA Receives U.S. FDA Clearance to Begin Phase 1 Clinical Trial of Pulmonary Arterial Hypertension Drug Candidate, VTB-10

By VASTHERA Co., Ltd.
VASTHERA Co., Ltd.
20 Aug 2025

Pharmaceutical

Asian Federation for Pharmaceutical Sciences 2025

03 Dec 2025 10:00 am - 05 Dec 2025 5:30 pm

Australia

Most Popular

Dr. Scott Grady Makes Thyroid RFA More Accessible in Oregon

By Portland Diabetes & Endocrinology Center

Feb 26
Illumina's Constellation Mapped Read technology uncovers hard-to-see genomic insights in the GeneDx pilot

By Illumina, Inc.

Oct 15
$SciTech Development announces the second FDA approval of a Phase 1 A/B IND for ST-001, which now targets the treatment of relapsed/refractory small cell lung cancer, following its previous approval for the treatment of T-cell NHL$

SciTech Development announces the second FDA approval of a Phase 1 A/B IND for ST-001, which now targets the treatment of relapsed/refractory small cell lung cancer, following its previous approval for the treatment of T-cell NHL

By SciTech Development, Inc.

Apr 08

November 2025

M	T	W	T	F	S	S
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

Search your requirement

Social media

MilliporeSigma receives the industry's first EXCiPACT certification for cell culture media manufacturing

Ibex Medical Analytics achieves notable milestones with its AI-first approach to cancer diagnostics

Albertsons Companies pharmacies now offer COVID and flu vaccines to help protect communities this respiratory virus season

OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award

Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis

ProJenX announces the formation of its Clinical Advisory Board

Citius Pharmaceuticals' LYMPHIR™ wins FDA approval for relapsed/refractory cutaneous T-cell lymphoma

NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients

Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits

Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.

Updated flu and COVID-19 vaccinations are now available at CVS Pharmacy® and MinuteClinic

FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma

Featured Press Releases

CorrectSequence Therapeutics' CS-101 Achieves Promising Results in First Patient: High-Precision Base Editing Clinical Treatment for Sickle Cell Disease

2025 Interim Results and Business Updates Announced by Innovent

Gvoke VialDx™ (glucagon injection) Launched by American Regent

Innovent Biologics announces U.S. FDA IND approval for Phase 3 MarsLight-11 study of IBI363 in squamous NSCLC

Theravance Biopharma completes enrollment in Phase 3 CYPRESS study of Ampreloxetine for neurogenic orthostatic hypotension

VASTHERA Receives U.S. FDA Clearance to Begin Phase 1 Clinical Trial of Pulmonary Arterial Hypertension Drug Candidate, VTB-10

Most Popular

Dr. Scott Grady Makes Thyroid RFA More Accessible in Oregon

Illumina's Constellation Mapped Read technology uncovers hard-to-see genomic insights in the GeneDx pilot

SciTech Development announces the second FDA approval of a Phase 1 A/B IND for ST-001, which now targets the treatment of relapsed/refractory small cell lung cancer, following its previous approval for the treatment of T-cell NHL

User Area

Discover

Engage with Us

Search your requirement

Social media

Featured Press Releases

Most Popular

User Area

Discover

Engage with Us

Subscribe for e-Newsletter Monthly